A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash
Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Salma Health raises $80M for its clinics to treat brain health
Salma Health raises $80M for its clinics to treat brain health
OrbiMed jumps to number one on the top 100 list of biotech venture investors
OrbiMed jumps to number one on the top 100 list of biotech venture investors
Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects
Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects
Japan's Asahi Kasei to buy German biotech Aicuris for $920M
Japan's Asahi Kasei to buy German biotech Aicuris for $920M
Sarepta CEO Doug Ingram to step down
Sarepta CEO Doug Ingram to step down
Gilead, Merck plan to debut new daily HIV pills
Gilead, Merck plan to debut new daily HIV pills
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug
Charles River sells its CDMO and European discovery businesses
Charles River sells its CDMO and European discovery businesses
Accent axes a cancer study; Werewolf considers its options
Accent axes a cancer study; Werewolf considers its options
Alkermes CEO Richard Pops to retire after 35-year tenure
Alkermes CEO Richard Pops to retire after 35-year tenure
States sue Kennedy over US childhood vaccine overhaul
States sue Kennedy over US childhood vaccine overhaul
Novo Nordisk teams with Langer-founded biotech for oral obesity drugs
Novo Nordisk teams with Langer-founded biotech for oral obesity drugs
Polymer nanoparticle startup BreezeBio raises $60M for mRNA diabetes therapy
Polymer nanoparticle startup BreezeBio raises $60M for mRNA diabetes therapy
GSK to buy pulmonary hypertension biotech 35Pharma for $950M
GSK to buy pulmonary hypertension biotech 35Pharma for $950M
HHS commits up to $144M to study anti-aging approaches via ARPA-H
HHS commits up to $144M to study anti-aging approaches via ARPA-H